Please login to the form below

Not currently logged in

dry eye

This page shows the latest dry eye news and features for those working in and with pharma, biotech and healthcare.

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Also in its Q2 update, Novartis reported on its drug pipeline, announcing that it would be abandoning a dry eye disease candidate – ECF843 – after phase 3 data failed to hit the

Latest news

More from news
Approximately 4 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    RNA‐targeted therapeutic, IONIS‐FB‐LRx targeting Factor. B, for Geographic Atrophy, an advanced form of dry Age-related Macular Degeneration (AMD). ... According to Bloomberg, the products Xiidra eyedrops for dry eye and Natpara for

  • The good, the bad and the ugly The good, the bad and the ugly

    Bayer’s growth - a healthy 14.6% - was stimulated by a steady performance by Xarelto in Europe and Asia, and strong sales of its eye medicine Eylea in Japan, Europe and ... In second position, Allergan experienced modest sales growth of 2.3%.

  • Pharma deals in July 2015 Pharma deals in July 2015

    The third deal by Allergan to bolster its pipeline was the acquisition of Occuleve, a medical device company with a product in late stage development for treating dry eyes. ... Company acquisition. Dry eye device. 125+. Novartis / Mereo. Divestment of

  • Pharma deals during March 2013 Pharma deals during March 2013

    However, ophthalmology is increasingly an area of interest in the industry with potential for growth as the global population ages; it is estimated that around 25m people have dry eye disease ... 175. SARcode Bioscience/ Shire. Acquisition. SAR 1118 for

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    Novartis focuses on high-growth areas in healthcare, spanning innovative pharmaceuticals, eye care, generics, consumer health, plus vaccines and diagnostics. ... R&D focus is on discovering new treatments for conditions including age-related macular

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....